Prevalence and Correlates of Post-Traumatic Stress Disorder Symptoms During the COVID-19 Pandemic in Canada: A Systematic Review and Meta-analysis: Prévalence et corrélats des symptômes du trouble de stress post-traumatique pendant la pandémie de COVID-19 au Canada : Revue systématique et méta-analyse.

Can J PsychiatryJan 28, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Jude Mary Cénat, Wina Paul Darius, Seyed Mohammad Mahdi Moshirian Farahi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and random-effects meta-analysis pooled findings from 30 studies conducted in Canada between 2020 and 2022, including 52,565 adults. The estimated prevalence of post-traumatic stress disorder symptoms during the COVID-19 pandemic was 22.2% (95% CI, 15.7% to 29.4%; I² = 99.69). Estimates were 32.1% in women and 26.1% in men, with no significant difference by sex. Prevalence also varied across provinces, while meta-regression found lower prevalence in Quebec. The authors caution that substantial between-study heterogeneity limits interpretation.

Key findings

  • Pooled PTSD symptom prevalence was 22.2% (95% CI, 15.7% to 29.4%; I² = 99.69).
  • Prevalence estimates were 32.1% in women and 26.1% in men (p = 0.399).
  • Provincial estimates ranged from 16.1% in Quebec to 29.7% in Ontario (p = 0.091); meta-regression found lower prevalence in Quebec (B=-0.16, p = 0.029).
  • No significant differences were found by healthcare worker status, assessment tool, or data collection year.

Why it matters

The pooled estimate indicates that PTSD symptoms were common across Canadian adults during the pandemic, while the absence of significant differences by sex or healthcare worker status suggests distress was not confined to those groups. However, the very high heterogeneity means the pooled figure should not be treated as a uniform estimate for every population or setting.

What to keep in mind

Substantial heterogeneity across studies (I² = 99.69) limits interpretation of the pooled prevalence and comparisons between groups or provinces.

Source

Published in Can J Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.